Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/37200
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYap C.-H.en
dc.contributor.authorSmith J.en
dc.contributor.authorBillah B.en
dc.contributor.authorYan B.P.en
dc.contributor.authorBrennan A.L.en
dc.contributor.authorTran L.en
dc.contributor.authorReid C.M.en
dc.contributor.authorParkinson B.en
dc.contributor.authorDuffy S.J.en
dc.contributor.authorRosenfeldt F.en
dc.contributor.authorHuq M.en
dc.contributor.authorAdemi Z.en
dc.contributor.authorAriyaratne T.V.en
dc.date.accessioned2021-05-14T12:38:54Zen
dc.date.available2021-05-14T12:38:54Zen
dc.date.copyright2018en
dc.date.created20180912en
dc.date.issued2018-09-12en
dc.identifier.citationApplied Health Economics and Health Policy. 16 (5) (pp 661-674), 2018. Date of Publication: 01 Oct 2018.en
dc.identifier.issn1175-5652en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/37200en
dc.description.abstractBackground: There are limited economic evaluations comparing coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for multi-vessel coronary artery disease (MVCAD) in contemporary, routine clinical practice. Objective(s): The aim was to perform a cost-effectiveness analysis comparing CABG and PCI in patients with MVCAD, from the perspective of the Australian public hospital payer, using observational data sources. Method(s): Clinical data from the Melbourne Interventional Group (MIG) and the Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) registries were analysed for 1022 CABG (treatment) and 978 PCI (comparator) procedures performed between June 2009 and December 2013. Clinical records were linked to same-hospital admissions and national death index (NDI) data. The incremental cost-effectiveness ratios (ICERs) per major adverse cardiac and cerebrovascular event (MACCE) avoided were evaluated. The propensity score bin bootstrap (PSBB) approach was used to validate base-case results. Result(s): At mean follow-up of 2.7 years, CABG compared with PCI was associated with increased costs and greater all-cause mortality, but a significantly lower rate of MACCE. An ICER of $55,255 (Australian dollars)/MACCE avoided was observed for the overall cohort. The ICER varied across comparisons against bare metal stents (ICER $25,815/MACCE avoided), all drug-eluting stents (DES) ($56,861), second-generation DES ($42,925), and third-generation of DES ($88,535). Moderate-to-low ICERs were apparent for high-risk subgroups, including those with chronic kidney disease ($62,299), diabetes ($42,819), history of myocardial infarction ($30,431), left main coronary artery disease ($38,864), and heart failure ($36,966). Conclusion(s): At early follow-up, high-risk subgroups had lower ICERs than the overall cohort when CABG was compared with PCI. A personalised, multidisciplinary approach to treatment of patients may enhance cost containment, as well as improving clinical outcomes following revascularisation strategies.Copyright © 2018, Springer International Publishing AG, part of Springer Nature.en
dc.languageenen
dc.languageEnglishen
dc.publisherSpringer International Publishingen
dc.relation.ispartofApplied Health Economics and Health Policyen
dc.titleThe Real-World Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Stenting in High-Risk Patients: Propensity Score-Matched Analysis of a Single-Centre Experience.en
dc.typeArticleen
dc.type.studyortrialObservational study (cohort, case-control, cross sectional or survey)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1007/s40258-018-0407-5en
dc.publisher.placeSwitzerlanden
dc.identifier.pubmedid29998450 [http://www.ncbi.nlm.nih.gov/pubmed/?term=29998450]en
dc.identifier.source622992065en
dc.identifier.institution(Ariyaratne, Ademi, Rosenfeldt, Duffy, Yap, Billah, Yan, Brennan, Tran, Reid) Department of Epidemiology and Preventive Medicine (DEPM), Centre of Cardiovascular Research and Education in Therapeutics (CCRE), Monash University, 6th Floor, 99 Commercial Rd, Melbourne, VIC 3004, Australia (Ademi) Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland (Huq) Department of Medicine, University of Melbourne, Melbourne, VIC, Australia (Rosenfeldt) Baker Heart and Diabetes Institute, Melbourne, VIC, Australia (Duffy) Department of Cardiovascular Medicine, Alfred Hospital, Melbourne, VIC, Australia (Parkinson) Macquarie University Centre for the Health Economy, Macquarie University, Sydney, NSW, Australia (Yap) Cardiothoracic Unit, Geelong Hospital, Geelong, VIC, Australia (Smith) Department of Surgery, School of Clinical Sciences, Monash Health, Monash University, Melbourne, VIC, Australia (Yan) Department of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Shatin, Hong Kong (Reid) School of Public Health, Curtin University, Perth, WA, Australiaen
dc.description.addressT.V. Ariyaratne, Department of Epidemiology and Preventive Medicine (DEPM), Centre of Cardiovascular Research and Education in Therapeutics (CCRE), Monash University, 6th Floor, 99 Commercial Rd, Melbourne, VIC 3004, Australia. E-mail: chris.reid@monash.eduen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2018 Elsevier B.V., All rights reserved.en
dc.identifier.authoremailAriyaratne T.V.; chris.reid@monash.eduen
item.openairetypeArticle-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
crisitem.author.deptCardiothoracic Surgery-
Appears in Collections:Articles
Show simple item record

Page view(s)

42
checked on Apr 26, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.